Osteology and Rheumatology

Open journal

ISSN 2996-5918

The Use of Botulinum Toxin-A for Neck Pain

Abdulrazzaq Alobaid*

Received: March 28th, 2016, Accepted: April 4th, 2016, Published: April 6th, 2016

Botulinum Toxin Type-A (BoNT-A) is widely used and has been approved in the field of facial esthetic as well as in some neurological conditions. Its neurotoxin protein produced by bacteria called Clostridium botulinum as this two chain protein blocks the acetylcholine release at the NMJ through its action of the SNARE proteins which by this will temporarily inhibit striatal muscle contraction. There are different commercially available preparations like; OnabotulinumtoxinA (BOTOX®), AbobotulinumtoxinA (Dysport®), and RimabotulinumtoxinB (Myobloc®).

Recently, there was an interest in utilizing it for muscular neck pain and headache. These conditions can be chronic and difficult to treat. Although there are more consensus on migraine and cervical dystonia, the literature showed conflicting results and conclusions.1,2 A randomized double-blinded study showed a trend toward improvement in the BOTOX® group.3 Another prospective study showed a significant reduction of pain intensity in patients receiving BoNT-A for refractory neck pain.4 One more randomized controlled study for chronic neck pain after “whiplash” injuries were demonstrated a statistically significant reduction in pain for the patients who were treated with BoNT-A compared with placebo.5 Contradicting results were found on other studies where the injected BoNT-A failed to provide significant improvement of neck pain. In a randomized, double-blinded study, injection of BoNT-A were directly triggered to the points did not improve cervicothoracic myofascial pain.6 Although many studies have shown it to be safe, the adverse effects remains a concern among physicians using these injections.

The role of direct injection of trigger points with BoNT-A for neck pain and spasm is still under progressive research and study. There could be a beneficial role for BoNT-A as an alternative treatment for resistant cases with chronic pain refractory to other modalities. Nowa-days, the clinical practice should follow evidence based medicine. A clear protocol including the type of toxin injected, suggested dose, concentration, and methods of injection should be established. A multi-centered study with controlled variables could help get more clear results.

 

1. Argoff CE. The use of botulinum toxins for chronic pain and headaches. Curr Treat Options Neurol. 2003; 5: 483-492. doi: 10.1007/s11940-996-0016-8

2. Sycha T, Kranz G, Auff E, Schnider P. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol. 2004; 251 Suppl 1: i19-i30. doi: 10.1007/s00415-004-1106-8

3. Lew HL, Lee EH, Castaneda A, Klima R, Date E. Therapeutic use of botulinum toxin type a in treating neck and upper-back pain of myofascial origin: A pilot study. Arch Phys Med Rehabil. 2008; 89(1): 75-80. doi: 10.1016/j.apmr.2007.08.133

4. Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study. Pain Med. 2009; 10 (6): 1012-1017. doi: 10.1111/j.1526-4637.2009.00658.x

5. Freund B, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache. 2000; 40: 231-236. doi: 10.1046/j.1526-4610.2000.00033.x

6. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology. 2005; 103: 377-383. Web site. http://anesthesiology.pubs.asahq.org/ article.aspx?articleid=1941955. Published August, 2005. Accessed March, 2016.

 

LATEST ARTICLES

Use of Black Soldier Fly (Hermetia illucens) Prepupae Reared on Organic Waste

review

2024 Mar

Isayas A. Kebede*, Haben F. Gebremeskel and Gelan D. Dahesa,
Figure 11. Risk Map for the Introduction of Ruminant Diseases at Borders

Original Research, peer reviewed

2024 Mar

Yassir Lezaar*, Mehdi Boumalik, Youssef Lhor, Moha El-Ayachi, Abelilah Araba and Mohammed Bouslikhane

Commentary, End-of-Life, Family Dynamics, palliative Care, peer reviewed

2024 Mar

Neil A. Nijhawan*, Rasha Mustafa and Aqeela Sheikh

Retrospective Study

2024 Mar

Shrenik J. Shah*, Abhishek Jha, Chirag Davara, Rushi Mistry and Kapil Kachhadiya

Attention, Disaster, Mindfulness, Original Research, peer reviewed

2024 Mar

Christina Hagen*, Lars Lien, Edvard Hauff and Trond Heir

review

2024 Mar

Isayas A. Kebede* and Gelan D. Dahesa

review

2024 Feb

Bekiyad S. Daro*; Yared A. Deneke, Jiregna G. Negasa and Ishetu N. Dibaba